• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cytosorbents Corporation - Common Stock (NQ:CTSO)

    0.6654 +0.0262 (+4.10%)
    Streaming Delayed Price Updated: 2:03 PM EST, Jan 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Cytosorbents Corporation - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
    The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing... 
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants
    1,417,208 Series A Right Warrants Exercised at $1.13 Per Share, Providing $1.6 Million in Aggregate Gross Proceeds 
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Rights Offering Begins
    To Participate, Eligible Stockholders Should Consult Their Broker or Financial Advisor in Advance of the Rights Offering Expiration on January 10, 2025 
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Announces Rights Offering
    Investors Must Hold or Buy CTSO Common Stock by Close of Nasdaq Trading on Friday, December 13, 2024 to Participate 
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
    From CytoSorbents; Converge Biotech
    Via GlobeNewswire
    News headline image
    CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
    DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025 
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
    CytoSorbents CFO Kathleen P. Bloch Retires 
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
    “Working to Save Lives Together” Theme Highlights Two Decades of Successful Collaboration with the International Medical and Research Communities to Help Patients Survive Life-Threatening Illnesses 
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
    By enabling more rapid and easy treatment, PuriFi is expected to increase the demand and sales of CytoSorbents’ leading CytoSorb® blood purification cartridge for critically ill patients in the... 
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Secures $20 Million Credit Facility
    Credit facility provides timely non-dilutive capital to support ongoing global commercialization of CytoSorb® as well as regulatory submissions and potential commercialization plans for DrugSorb™-ATR... 
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
    Brings a powerful blood purification technology used to treat critically ill and cardiac surgery patients in nearly a quarter million treatments across 75 countries to date to one of the most... 
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
    From CytoSorbents
    Via GlobeNewswire
    News headline image
    CytoSorbents Reports First Quarter 2024 Results
    From CytoSorbents
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.